Journal of Neurology Neurosurgery and Psychiatry

Article	Citations
35 Processing speed (PS) improvement in alcohol related brain damage (ARBD)	116
Navigating the presymptomatic frontier in genetic ALS and FTD	93
#3115 Systematic review into the effects of sleep disorders on the development of PTSD	86
086 Long-term efficacy of fremanezumab in migraine patients with inadequate response to prior preventive medication classes	83
164  Progressive multifocal leukoencephalopathy (PML) following autologous periph- eral blood stem cell transplantation for multiple myeloma	81
West is best – a strongman with numb feet	79
094  Measuring neutralising antibodies (NAbs) to interferon-beta (IFNB) for multiple sclerosis (MS): a neglected practice?	76
099  Safety and effectiveness of dimethyl fumarate in multiple sclerosis patients treated over 5 years	74
005  Infusion associated reactions in ocrelizumab-treated multiple sclerosis patients	74
122  Neurological manifestations of haemophagocytic lymphohistiocytosis	70
White matter hyperintensities and brain microbleeds in ataxia-telangiectasia: the Cambridge cohort	68
102  The cost of misdiagnosis in POEMS syndrome	68
001  Machine learning accurately determines the population prevalence of Alzheimer’s disease based on microbiome profile	67
143  Catastrophising cognitions in patients with psychogenic non-epileptic seizures compared to patients with epilepsy	64
010  Safety and efficacy of long-term dimethyl fumarate treatment	60
184  Right data, right care	60
201  Management of an unusual presentation of spontaneous intracranial hypotension (SIH)	60
238  Cogniton and mood disorder in cervical dystonia	59
12 A pilot investigation of interoceptive accuracy, awareness, and sensibility in functional neurological disorder	57
L-arginine and mitochondrial encephalomyopathy, lactic acidosis and stroke- like episodes (MELAS): a systematic review	57
Improving clinical practice with an old friend from the neuroimmunology toolkit: acute corticosteroids in LGI1 antibody encephalitis	56
Multiple sclerosis reactivations after fingolimod discontinuation for pregnancy planning	56
Characterising ALS disease progression according to El Escorial and Gold Coast criteria	55
091 The East London Parkinson’s disease project – engaging a diverse population in research	54
175 A case series of anti-HMGCR immune mediated necrotizing myopathy: the West Midlands data	54

102 Levodopa and melanoma what do clinicians think?	53
059 Cannabidiol in refractory adult epilepsies: broadening the Lennox-Gastaut phenotype?	53
Improved naming in patients with Broca’s aphasia with tDCS	51
Haemorrhagic myelitis as a manifestation of MOG antibody-associated disease	51
117 Who is the culprit – the virus or the anti-virus?	51
Correction: The future of neuroprotection in stroke	50
226  Reduced synaptic density in progressive supranuclear palsy and corticobasal syndrome, revealed by [11C]UCB-J PET	50
Decrease of natalizumab drug levels after switching from intravenous to subcutaneous administration in patients with multiple sclerosis	47
091  CIDP mimic in a patient with HIV; An unusual presentation of POEMS syndrome	46
101 Motor and non-motor features of prodromal PD	45
Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis	43
003  Neuroanatomical signatures of genetic risk for Alzheimer’s disease in healthy adults	43
114  Effect of siponimod on cognitive processing speed in SPMS patients with active and non-active disease	42
Environmental risk scores of persistent organic pollutants associate with higher ALS risk and shorter survival in a new Michigan case/control cohort	42
Sodium valproate is associated with cortical thinning of disease-specific areas in juvenile myoclonic epilepsy	42
Neural (re)organisation of language and memory: implications for neuroplasticity and cognition	42
Early treatment of type II SMA slows rate of progression of scoliosis	41
Genetics of validated Parkinson’s disease subtypes in the Oxford Discovery and Tracking Parkinson’s cohorts	40
Impact of the COVID-19 pandemic on the prescription of disease-modifying therapy for multiple sclerosis in England: a nationwide study	40
De novo mutations in SOD1 are a cause of ALS	39
High frequency ofHTRA1ANDABCC6mutations in Japanese patients with adult-onset cerebral small vessel disease	39
052 SKYLINE study design efficacy and safety of gantenerumab in participants at-risk for Alzheimer’s disease	39
3 The role of neuroimaging and neuromodulation	39
The Scottish Epilepsy Deaths Study Score (SEDS Score): a risk prediction model for epilepsy-related deaths	39
Evaluation of MDS-PSP diagnostic criteria in a combined behavioural neurology and atypical parkinsonism service	38
005 A case of xanthomatous hypophysitis presenting as recurrent pituitary adenoma	38
066 The Utility of 18-FDG PET imaging in the preoperative workup for epilepsy surgery	38
055 Assessment of MACE cognitive screener using efficiency indexes	38
178 Motor neurone disease and sociodemographic factors: a review	38
009 Asymmetric peri-optic cerebrospinal fluid space distension in cluster headache	37
106 Critical ischaemia without infarction presenting as progressive hemichorea: a case study and literature review	36
096  Maintenance IVIg safe prescribing – audit of proforma and traffic light risk assessment system in NHNN	36
132 Adverse prognostic factors predicting disease modifying therapies in MS: a real- world cohort	36
039  Cerebral venous sinus thrombosis and COVID-19: causation or coincidence?	35
Late-onset epilepsy predicts future stroke: a systematic review and meta-analysis	35
235  Assessing coding of diagnosis for atypical parkinsonian syndromes	35
161  Two-centre audit of cannabidiol use in adults with Dravet syndrome	35
259  A novel mutation of protein kinase C gamma associated with spinocerebellar ataxia type 14	35
016  Long-term disease stability in patients treated with cladribine tablets in CLARITY and CLARITY extension	34
084  Is there a positive correlation between single breath count and forced vital capacity?	34
Good outcomes after aggressive treatment of immune checkpoint inhibitor related myasthenia gravis: a case series	34
40 Temporal discounting and male depression	33
Effects of VNS stimulation on electrocorticography in patients with dual neuro- stimulation devices	33
006  Seizure focus prediction from seizure semiology: data-driven cortical probabilis- tic heatmaps from 4643 patients	33
#3097 Temporal and spectral dynamics of reward and risk processing in the amygdala revealed with stereo-EEG recordings in epilepsy	33
239  New de novo mutation in CACNA1a gene leading to episodic ataxia type 2	33
Real-world experience of gene therapy with onasemnogene-abeparvovec (Zolgensma®) for patients with SMA-type1 in UK	32
Neuromodulation for the treatment of functional neurological disorder and somatic symptom disorder: a systematic review	32
110  UK multiple sclerosis service audit of 70 centres: MS-MDTs	32
Influence of cardiorespiratory fitness and MRI measures of neuroinflammation on hippocampal volume in multiple sclerosis	32

5 Sex, bugs & microwave attacks: how bad science, mating insects & psychogenic illness created an international incident with cuba	32
Genetics of inherited peripheral neuropathies and the next frontier: looking backwards to progress forwards	32
Aquaporin-4–neuromyelitis optica spectrum disorder is not a progressive disease	31
Association of obesity with mild traumatic brain injury symptoms, inflammatory profile, quality of life and functional outcomes: a TRACK-TBI Study	30
Can brain signals and anatomy refine contact choice for deep brain stimulation in Parkinson’s disease?	30
Comparative neural correlates of DBS and MRgFUS lesioning for tremor control in essential tremor	30
Risk of stroke in multiple sclerosis and neuromyelitis optic spectrum disorder: a Nationwide cohort study in South Korea	30
Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry	30
Induction cyclophosphamide with maintenance immunosuppression in high-risk myasthenia gravis: long-term follow-up and safety profile	29
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with autoantibody-mediated neuroimmunology	29
CIDP trials and tribulations	29
Temporal lobe epilepsy lateralisation and surgical outcome prediction using diffusion imaging	29
Dissociative seizures in the emergency room: room for improvement	29
Spinal cord motor neuron phenotypes and polygenic risk scores in sporadic amyotrophic lateral sclerosis: deciphering the disease pathology and therapeutic potential of ropinirole hydrochloride	28
Beyond antithrombotics: recent advances in pharmacological risk factor management for secondary stroke prevention	27
Muscle biochemical and pathological diagnosis in Pompe disease	27
Multiple sclerosis: structural and functional integrity of the visual system following alemtuzumab therapy	27
Factors affecting the risk of relapsing-onset and progressive-onset multiple sclerosis	27
Longitudinal trajectory of depression symptom severity and the influence of concussion history and physical function over a 19-year period among former National Football League (NFL) players: an NFL-L	27
Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders	27
Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies	26
Prognostic relationship of neurofilaments, CHIT1, YKL-40 and MCP-1 in amyotrophic lateral sclerosis	26
Cluster analysis showed long-term cognition can be predicted by looking at regional grey matter atrophy in the first two years of multiple sclerosis course	26
Possible predictors of phenoconversion in isolated REM sleep behaviour disorder: a systematic review and meta-analysis	26
028 Croydon neurology diagnostic coding of outpatients – the first year of experience	25
Lacunar stroke: mechanisms and therapeutic implications	25
021 Experience from a SARS-CoV2 neurology clinic at the national hospital of neurology and neurosurgery	25
Serum GFAP differentiates Alzheimer’s disease from frontotemporal dementia and predicts MCI-to-dementia conversion	25
Evoked mid-frontal activity predicts cognitive dysfunction in Parkinson’s disease	25
Psychiatric symptoms in multiple sclerosis: a biological perspective on synaptic and network dysfunction	25
What, when and how should the information about neurodegenerative disease risk in iRBD be communicated?	24
099 Thrombotic and haemorrhagic complications associated with PLEX, reducing the risks	24
114 Pain and objectively measured cognitive performance in adults with multiple sclerosis: a systematic review	24
010 Trigeminal neuralgia in diffuse scleroderma – a rare but recognised association	24
049 Hippocampal place cell dysfunction in an APP knock-in mouse model of Alzheimer’s disease	24
142 Discordance between neurologists and people with MS on the presence and burden of cognitive impairment	24
171 Urinary P75: a novel biomarker for motor neuron disease?	23
156 Association of locus of control with clinical and psychosocial aspects of living with multiple sclerosis	23
219  MRI monitoring in MS patients prescribed disease monitoring treatments in Kings College Hospital	23
222  DECISIve – DiagnosE using the Central veIn SIgn. A study comparing T2* MRI and lumbar puncture	23
017  Year 1 performance of adveva® programme for patients taking cladribine tablets for relapsing-remitting multiple sclerosis	22
258  A case of two brothers: should we look beyond a diagnosis of cerebral palsy?	22
Biomarkers for brain injury and copper toxicity in Wilson’s disease: a diffusion tensor imaging study	22
026  Gene-environment interactions in multiple sclerosis: a UK Biobank study	21
244  Idiopathic anosmia with motor impairment – a unique prodrome of Parkinson’s?	21
046  Familial multiple sclerosis: a community-based epidemiology study in Cumbria	21
009  Abnormal blood-brain barrier permeability in progressive multiple sclerosis	21
022  Functional genomics and transcriptomics further characterise and potentially improve diagnostic yield of hereditary ataxias	21
199  Improving training in systems leadership management: a ‘Mini-Darzi’ approach	21
103  Virtual multiple sclerosis (MS) clinics during a global pandemic: the patients’ perspective	20
Factors associated with outcomes following autologous haematopoietic stem cell transplantation for multiple sclerosis	20
024  CLARITY study: efficacy outcomes among patients receiving disease-modifying therapies prior to treatment with cladribine tablets	20
Expanding the therapeutic toolkit in functional neurological disorder: consensus recommendations for speech and language therapy	20
170  Did the atraumatic lumbar puncture needle campaign have any effect?	20
MRI lesions can often precede trigeminal neuralgia symptoms by years in multiple sclerosis	20
Searches for biomarkers using highly sensitive techniques might reveal more about pathogenesis of a disease than provide clinically useful molecular tests	19
185 JEWELFISH: Safety, pharmacodynamic and exploratory efficacy data in non-naïve patients with SMA receiving risdiplam	19
Validation of the hotspot for dorsolateral subthalamic nucleus targeting in deep brain stimulation surgery for Parkinson’s disease: a post hoc analysis of a randomised controlled trial	19
Unhealthy traits and risk of Parkinson’s disease: a mendelian randomisation study	19
124  Symptoms of post-traumatic stress disorder are common after being diagnosed with multiple sclerosis	19
How effective is effective enough?	19
047 Clinicopathological characteristics impacting on survival in sporadic CJD: insights from an international autopsy-confirmed series	19
Insufficient sleep during adolescence and risk of multiple sclerosis: results from a Swedish case-control study	19
091  Evaluation of remote assessments for multiple sclerosis in a real-world setting	19
Functional disorders after COVID-19 vaccine fuel vaccination hesitancy	19
Towards multicentre diffusion MRI studies in cerebral small vessel disease	19
08 The economic cost of functional neurological disorders: a systematic review introduction	19
APOE ɛ4dose associates with increased brain iron and β-amyloid via blood–brain barrier dysfunction	19
187  Variation in training: Results from a survey of UK neurology trainees	19
A novel neurodegenerative disease with multi-system features	18
058 Does prolonging duration of monitoring in epilepsy monitoring unit improve diagnostic yield?	18
104  A case of natalizumab-related progressive multifocal leukoencephalopathy treated with pembrolizumab	18
128 Visuoperceptual deficits as measures of cognitive dysfunction in multiple sclerosis: a pilot study	18
135  A national audit of service provision for patients with atypical parkinsonian syndrome	18
Attenuated heart-brain integration predicts functional non-epileptic seizures	18
054 Baseline characteristics of the Phase III GRADUATE studies: investigating subcu- taneous gantenerumab in early AD	18
032  Improving access to inpatient ambulatory cardiac monitoring for acute stroke patients during the Covid-19 pandemic	18
078  The future of outpatient appointments: do patients with epilepsy prefer remote consultations?	18
064 Epilepsy and sociodemographic factors a review	18
126 The provision of anti-CD20 therapy in inflammatory demyelinating disorders of the CNS during SARS-CoV-2	18

080 IIH Life A prospective longitudinal cohort study of idiopathic intracranial hypertension	18
030  Hepatitis C reactivation with fingolimod treatment for relapsing-remitting multiple sclerosis (RRMS)	17
039  Disease modifying treatments and cancer monitoring in MS; the need for a nation-wide disease registry	17
225  A rare case of recurrent unsteadiness due to Miller Fisher syndrome	17
14 Saving Adam from the apple: using transcranial magnetic stimulation as a transdiagnostically relevant tool to decrease cue-reactivity	17
11 The experience of hearing life altering medical news? Perspectives from health professionals	17
125  Towards an optimal multiple sclerosis patient case-load for a full-time MSologist	17
124  MEGAbIT – the role of OPM MEG in assessment and diagnosis In mTBI	17
043  Efficacy of siponimod in secondary progressive multiple sclerosis with active disease: EXPAND study subgroup analysis	17
Effects of immunotherapies and clinical outcomes in neurosarcoidosis : a retro- spective cohort study	17
25 ‘In a mist?’ – What is ‘brain fog’?	17
Functional (psychogenic non-epileptic/dissociative) seizures: why and how?	17
117  Sustained and rapid B-cell depletion with ofatumumab: population pharma- cokinetic B-cell modeling in relapsing MS patients	17
044  Analysis of urgent acute medicine and ward referrals to neurology at the district hospital	17
A composite clinical motor score as a comprehensive and sensitive outcome measure for Parkinson’s disease	17
24 Intelligent sensing in ADHD trial (ISAT) – pilot study	17
Functional tremor developing after successful MRI-guided focused ultrasound thalamotomy for essential tremor	17
Investigating colour vision and its structural correlates 15 years following a first demyelinating event	16
Prescription opioid use in multiple sclerosis	16
Childbirth delivery mode and the risk of multiple sclerosis: a prospective population-based study	16
Brain neuronal and glial damage during acute COVID-19 infection in absence of clinical neurological manifestations	16
Dynamics of choroid plexus volume is associated with the presence and development of fatigue in multiple sclerosis	16
Clinical relevance of distinguishing autoimmune nodopathies from CIDP: longitudinal assessment in a large cohort	16
Visuospatial dysfunction predicts dementia-first phenoconversion in isolated REM sleep behaviour disorder	16
Ultrasensitive assay technology and fluid biomarkers for the evaluation of peripheral nerve disease	16
IVIg-exposure and thromboembolic event risk: findings from the UK Biobank	16
Can CANVAS due toRFC1biallelic expansions present with pure ataxia?	16
Risk of secondary progressive multiple sclerosis after early worsening of disability	16
Peripheral hearing loss at age 70 predicts brain atrophy and associated cognitive change	15
Association between heavy alcohol consumption and cryptogenic ischaemic stroke in young adults: a case–control study	15
Postoperative de novo epilepsy after craniotomy: a nationwide register-based cohort study	15
Choroid plexus enlargement in paediatric multiple sclerosis: clinical relevance and effect of sex	15
Epigenetic clocks in neurodegenerative diseases: a systematic review	15
Gene–environment interactions increase the risk of paediatric-onset multiple sclerosis associated with household chemical exposures	15
Association between early treatment of multiple sclerosis and patient-reported outcomes: a nationwide observational cohort study	15
Spasticity treatment patterns among people with multiple sclerosis: a Swedish cohort study	15
Stratifying quality of life outcome in subthalamic stimulation for Parkinson’s disease	15
Effect of sodium phenylbutyrate and taurursodiol on plasma concentrations of neuroinflammatory biomarkers in amyotrophic lateral sclerosis: results from the CENTAUR trial	15
Iatrogenic cerebral amyloid angiopathy: an emerging clinical phenomenon	15
130  Does visual imagery vividness have a genetic basis? A genome-wide associa- tion study of 1019 individuals	15
Statin use and long-term risk of recurrent intracerebral haemorrhage: the MUCH-Italy	14
Beware next-generation sequencing gene panels as the first-line genetic test in Charcot-Marie-Tooth disease	14
6 PTSD and war photo journalists	14
032 Supine hypertension and cardiovascular autonomic failure in patients with alpha-synucleinopathies	14
Telomere length, in vivo Alzheimer’s disease pathologies and cognitive decline in older adults	14
Therapeutic interventions increasing seizure risk in multiple sclerosis: resolving discordant meta-analyses	14
153 ChariotMS – cladribine to halt deterioration in people with advanced multiple sclerosis (pwAMS)	14
Incidence and prevalence of paediatric-onset multiple sclerosis in two Canadian provinces: a population-based study representing over half of Canada’s population	14
Neurocognitive and psychiatric outcomes associated with postacute COVID-19 infection without severe medical complication: a meta-analysis	14
Multiparametric quantitative MRI reveals progressive cortical damage over time in clinically stable relapsing-remitting MS	14
Comparison of relative change with effect size metrics in Alzheimer’s disease clinical trials	14
044 At what resolution does the brain perform computations?	14
Do lower limb motor-evoked potentials predict walking outcomes post-stroke?	13
Neurite orientation dispersion and density imaging discloses early changes in the normal-appearing white matter in paediatric multiple sclerosis	13
006 A novel approach in the management of functional neurological disorder in the hyper-acute setting	13
070  What is seronegative neuromyelitis optica spectrum disorder?	13
074  Long-term effect of idebenone in reducing respiratory function decline in patients with Duchenne muscular dystrophy	13
Validation of MATCH score: a predictive tool for identification of patients with kelch-like protein-11 autoantibodies	13
#3108 Initial assessment structure in a specialist outpatient clinic for acquired brain injury in adults	13
Clinical biomarker-based biological ageing and future risk of neurological disorders in the UK Biobank	13
003  Systemic inflammation, erythrocyte fragility and multiple sclerosis	13
195  Delayed transfer of care (DToC) in neuroscience across South London: an insight through patient journeys	13
Silent progression of brain atrophy in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder	13
056 Online assessment and monitoring of cognitive decline in neurological conditions	13
035  Diagnosis of secondary progressive multiple sclerosis in UK centres: results from the SPECTRUM project	13
Genomic features specific to the human lineage are associated with neurological diseases and intelligence	13
247  Unusual presentation to an emergency department	12
04 Should neuropsychiatry flow both ways? Neurology inreach into psychiatric hospital	12
Structural and functional alterations in the gustatory network underlie taste disturbances after lesional tremor therapy with MRgFUS	12
147 Siponimod preserves retinal thickness: findings from the EXPAND OCT substudy	12
135  CMT with renal impairment: consider a dip	12
242  A systematic review on the benefit of multidisciplinary care for patients with atypical parkinsonian syndromes	12
212  Preventing blindness for patients with optic disc swelling: improving care using transformative new technology	12
Sequencing of and escalation paradigms for MS therapies: time for a rethink?	12
8 Integrating dimensions of interoception in neuropsychiatry	12
Time to treat the climate and nature crisis as one indivisible global health emergency	12
086  Thymectomy in myasthenia gravis – a review of 36 patients	12
011  Progressive myoclonic epilepsy due to rare mitochondrial ND6 mutation, m.14487T>C	12
30 Dissociation and its biological and clinical correlates in functional neurological disorder: a systematic review and meta-analysis	12
204  Idiopathic intracranial hypertension in Wales: population characterisation, epidemiological trends and healthcare utilisation	12
37 The medicolegal challenges in neuropsychiatry: an evaluation of mental capacity and legal frameworks	12
030  Emerging parkinsonism in the PREDICT-PD cohort after 5-year follow-up	12
Strong association with remote EBV infection in children with MS as opposed to other acquired demyelinating disorders	11
023 Impact of pandemic on neurologists and neurology practice	11
Comparative whole transcriptome analysis of Parkinson’s disease focusing on the efficacy of zonisamide	11
Parallel Session 2: Neurodegeneration| Wed 18 May, 1115 – 1230|4 Novel complex motor behaviours in LGI1-autoantibody encephalitis	11
164 The role of MEG in assessment and diagnosis in mTBI	11
42 Inhibition of personal memory retrieval in dissociative amnesia: a study of two cases	11
The T1-weighted/T2-weighted ratio as a biomarker of anti-NMDA receptor encephalitis	11
Reward and actions and the game of life	11
073 Fenfluramine exhibits disease-modifying effects in a mouse model of Dravet syndrome	11
152 AttackMS natalizumab for the treatment of people with inflammatory demyeli- nation suggestive of multiple sclerosis	11
A roadmap to ALS prevention: strategies and priorities	11
Functional neurological disorders after COVID-19 and SARS-CoV-2 vaccines: a national multicentre observational study	11
100 Antiphospholipid-related chorea	11